Hence, in NSCLC cells, the decreased viability of cells treated with the combination of cisplatin and compound 1 is likely due to mitochondrial-independent mechanisms, i.e., the intracellular accumulation of cisplatin caused by the inhibition of ABCC1 by CORM. Here, ABCC1 is linked to non-small cell lung carcinoma.